The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -538,303 | - |
| Stock-based compensation | 98,385 | - |
| Loss on extinguishments of debt | -21,155 | - |
| Noncash interest expense on deferred royalty obligations | 86,460 | - |
| Amortization of debt discount and issuance costs | 4,515 | - |
| Depreciation and amortization | 3,999 | - |
| Noncash lease expense | 3,443 | - |
| Net loss from equity method investments | -51,579 | - |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | 11,062 | - |
| Noncash income from an equity method investment | 7,769 | - |
| Gain on deconsolidation of subsidiaries | 0 | - |
| Gain from investment in equity securities, net | 0 | - |
| Other noncash adjustments, net | 1,217 | - |
| Accounts receivable, net | 111,796 | - |
| Inventories | 23,356 | - |
| Prepaid expenses and other current assets | 17,527 | - |
| Other assets | -568 | - |
| Accounts payable | 9,084 | - |
| Accrued compensation and benefits | 3,212 | - |
| Accrued research and development liabilities | 347 | - |
| Operating lease liabilities | -4,757 | - |
| Deferred revenue | -9,480 | - |
| Other liabilities | 53,030 | - |
| Net cash used in operating activities | -389,490 | - |
| Purchases of marketable securities | 10,876 | - |
| Maturities of marketable securities | 8,000 | - |
| Purchases of investments in equity securities | 0 | - |
| Proceeds from sales of investments in equity securities | 0 | - |
| Proceeds from special cash dividends received from an investment in equity securities | 2,302 | - |
| Payment for intangible assets | 8,495 | - |
| Purchases of property and equipment | 1,064 | - |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | 0 | - |
| Net cash provided by (used in) investing activities | -10,133 | - |
| Proceeds from issuance of 2031 notes-A2031Convertible Senior Notes | 575,000 | - |
| Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-A2031Convertible Senior Notes | 12,034 | - |
| Repurchase of common stock | 48,276 | - |
| Proceeds from a royalty obligation under the royalty purchase agreement | 300,000 | - |
| Issuance costs associated with a royalty obligation under the royalty purchase agreement | 3,010 | - |
| Proceeds from term loan under the amended financing agreement-Financing Agreement | 0 | - |
| Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-Financing Agreement | 0 | - |
| Repayment of term loans | 459,000 | - |
| Repayments of deferred royalty obligations | 6,896 | - |
| Proceeds from issuance of common stock through public offerings, net | 0 | - |
| Proceeds from common stock issuances under espp | 6,414 | - |
| Proceeds from stock option exercises, net of repurchases | 14,523 | - |
| Transactions with noncontrolling interests | 1,550 | - |
| Repurchase of rsu shares to satisfy tax withholding | 6,796 | - |
| Restricted cash, noncurrent | - | 1,698 |
| Net cash provided by financing activities | 361,475 | - |
| Restricted cash, current | - | 449 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -38,148 | - |
| Cash and cash equivalents, at carrying value, ending balance | - | 748,953 |
| Cash and cash equivalents at beginning of period | 683,244 | - |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents | - | 751,100 |
| Cash and cash equivalents at end of period | 645,096 | - |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)